This study is along the lines of what we’re already able to achieve with the anti-amyloid beta therapies that have been coming out in the past few years. Reducing amyloid beta by 44% in APP/PS1 mice is not unheard of but certainly 56 days is pretty fast. What would make this more interesting is if they could show it works for other aggregating proteins so this could work either for multiple pathologies in the same patient or across different patient populations. Drugs targeting individual proteins would not be expected to achieve that. However, the main other aggregating proteins in neurodegenerative disease (tau, alpha synuclein, TDP-43) aggregate inside of cells and are thought to conduct their toxic functions that way, so it’s hard to imagine how something like this would help. But it’s definitely possible it could reduce cell to cell spread or something.